More on the Disregard Syndrome

Editor's Note: All of these letters relate to the Opinion article, "The Disregard Syndrome: A Menace to Honest Science?" by Isaac Ginsburg, published in the Dec. 10, 2001 issue of The Scientist. See also, "Demand Citation Vigilance," a commentary by Eugene Garfield. Two common variants of the disregard syndrome deserve explicit identification. The "but see" variant typically involves a citation sequence such as "Much work supports this idea (Alpha 1991, Beta 1992, Gamma 1993—but see Delta

Written byRaymond O'connor
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Although widespread recourse to this tactic of laziness would make for very short citation half-lives, my impression is that the practice is spreading: I expect soon to see work from The Origin of Species attributed to a contemporary researcher in the form "Natural selection is known to lead to the survival of the fittest (Smith 2002)." Both this practice and the "But see" one should be recognized and criticized for what they are: serious departures from ethical standards of science.

When the whole flap over forging data occurred in the United States back in the 1980s, the blue ribbon panel formed at Harvard University to address the problem concluded that this was due, in part, to the fact that people were not doing master's theses anymore. So there was no one trying to reproduce others' experiments systematically.

The answer would be to put rigor back in to the training process.

...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies